| Pair Name | Thymoquinone, Doxorubicin | ||
| Phytochemical Name | Thymoquinone (PubChem CID: 10281 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Thymoquinone, Doxorubicin | |||
| Disease Info | [ICD-11: 2B33.3] | Acute lymphoblastic leukemia | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | CDH13 | hsa1012 |
| Down-regulation | Expression | MKI67 | hsa4288 | |
| In Vitro Model | HuT 102 | Mycosis fungoides | Homo sapiens (Human) | CVCL_3526 |
| Jurkat | Childhood T acute lymphoblastic leukemia | Homo sapiens (Human) | CVCL_0065 | |
| In Vivo Model | 7.5×10⁶ HuT-102 tumor cells in 100 ul Media:Matrigel (1:1 ratio) were inoculated subcutaneously in the right flank of NOD/SCID mice (6-8 weeks, 20 g) | |||
| Result | Our combination model offers the possibility to use up to twofold lower doses of Dox against ATL while exhibiting the same cancer inhibitory effects. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms. Life Sci. 2019 Sep 1;232:116628. doi: 10.1016/j.lfs.2019.116628. | Click |
